Case Series
 | What Are the Priorities for the Patient with Renal Impairment and Hypercalcemia? CME, CPE David Vesole, MD, PhD, FACP | |
| Release Date: August 14, 2014 Expiration Date: August 14, 2015 | ||
Reviewed: January 17, 2017 for clinical relevance; CE is expired. This case study will assist you in navigating the diagnosis, risk-stratification, prognosis, and individualized treatment planning of a challenging but not uncommon case of a 68-year-old male with a history of diabetes and cardiovascular disease, and who presents with newly diagnosed myeloma with poor risk genetic features, heavy disease burden, and extensive end organ damage including hypercalcemia, renal impairment, anemia, and bone lesions.Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||
 | Is this Multiple Myeloma? CME, CPE Parameswaran Hari, MD | |
| Release Date: February 18, 2014 Expiration Date: February 18, 2015 | ||
Reviewed: January 17, 2017 for clinical relevance; CE is expired. Join Parameswaran Hari, MD, in a patient case discussion where you will be challenged to determine whether the patient is a smoldering (asymptomatic) myeloma or active (symptomatic) myeloma patient. Recent updates to the definition of smoldering myeloma, advances in the management of smoldering myeloma, and the current recommended approaches to treatment and management of this particular group of patients are reviewed.Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||
 | What to do for Patients Who Delay Stem Cell Transplant CME, CPE Sergio A. Giralt, MD | |
| Release Date: January 30, 2014 Expiration Date: January 30, 2015 | ||
Reviewed: January 17, 2017 for clinical relevance; CE is expired. Join Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, for an important discussion regarding education and treatment planning for patients eligible for high-dose therapy with autologous stem cell transplant support who opt not to undergo the procedure up-front, and how treatment management plans may be adjusted, based on current clinical understanding, to meet individual patient needs while preserving future treatment options in eligible patients.Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation. | ||